10 September 2019

Re: Arrow-lamotrigine to remain fully funded until 30 September 2019 and available for private purchase.

Teva Pharma (New Zealand) Ltd (Teva) would like to advise that Arrow-lamotrigine 25mg, 50mg and 100mg will remain fully funded until 30 September 2019 and will be available for private purchase after this date.

For patients that wish to remain on Arrow-lamotrigine after this date, we have reduced the price of the 25mg, 50mg and 100mg to ensure better accessibility and affordability for patients.

Please note that the pricing here is the ex- manufacturer price and is not the final price to patients after 30 September 2019, as it will be subject to the individual pharmacy's mark-ups, fees and GST.

Product	Pharmacode	Current List price (ex GST) until 30 September	New Ex-manufacturer price (ex GST) from 1 October
Arrow-lamotrigine 25mg	2245515	$20.40	$14.00
Arrow-lamotrigine 50mg	2245507	$34.70	$15.50
Arrow-lamotrigine 100mg	2245493	$59.90	$16.25

Should you have any queries, please do not hesitate to contact our customer support team at enquiries@actavis.co.nz .

Yours Sincerely,

John Wickens

Teva Pharma (New Zealand) Ltd

Arrow-lamotrigine® (lamotrigine) is a Prescription Medicine, for adjunctive therapy in the treatment of epilepsy, for partial and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut Syndrome; for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes. *Arrow-lamotrigine* is a fully funded medicine without restriction and is available in 2mg, 5mg, 25mg, 50mg and 100mg tablets. **CONTRAINDICATIONS:** hypersensitivity to lamotrigine. **WARNINGS AND PRECAUTIONS:** High initial doses of lamotrigine and exceeding the recommended dose escalation of lamotrigine are associated with adverse skin reactions, usually within the first 8 weeks after initiation of lamotrigine (Arrow-lamotrigine) treatment. These have included potentially life-threatening rashes such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Evaluate any patient developing rash; withdraw lamotrigine unless it is clearly not drug related. Abrupt withdrawal may provoke rebound seizures. Possible interference with folate metabolism during long term use. Caution in severe renal failure; not recommended in significant hepatic impairment; monitor patients for signs of suicidal ideation or behaviour; monitor bipolar patients for clinical worsening. **ADVERSE EFFECTS:** Common: Headache, tiredness, rash (usually maculopapular), aggression, irritability, somnolence, ataxia, dizziness, nystagmus, tremor, insomnia, diplopia, blurred vision, nausea, vomiting, diarrhoea, agitation, arthralgia, pain and back pain. Rarely: conjunctivitis, serious potentially life-threatening skin rashes, including Stevens Johnson syndrome and toxic epidermal necrolysis (Lyell Syndrome). Very rarely: haematological disorders, lymphadenopathy, hypersensitivity syndrome, tics, hallucinations, confusion, aseptic meningitis, worsening of Parkinson's disease, hepatic dysfunction, hepatic failure and lupus-like reactions. Before prescribing Arrow-lamotrigine, please review the Data Sheet at www.medsafe.govt.nz. Arrow-lamotrigine is a registered trade mark of the Teva group of companies. Marketed by Teva Pharma (New Zealand) Limited, Auckland. **Adverse events involving Teva products should be reported to Teva Medical Information on 0800 800 097.**